XML 43 R32.htm IDEA: XBRL DOCUMENT
v3.25.1

EQUITY SECURITIES PORTFOLIO INVESTMENT (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Investments, Debt and Equity Securities [Abstract] |
Unrealized Gain (Loss) on Investments | Equity securities for the periods presented were comprised of the following:
Security Type | Cost |  | Gross Unrealized Gain |  | Gross Unrealized Loss |  | Fair Value
| (In thousands)
March 31, 2025: |  |  |  |  |  |  |
Equity securities - other common stock | $ | 24,605 |  |  | $ | 20 |  |  | $ | (6,561) |  |  | $ | 18,064 |
Total | $ | 24,605 |  |  | $ | 20 |  |  | $ | (6,561) |  |  | $ | 18,064 |
December 31, 2024: |  |  |  |  |  |  |
Equity securities - other common stock | $ | 24,898 |  |  | $ | 118 |  |  | $ | (1,881) |  |  | $ | 23,135 |
Total | $ | 24,898 |  |  | $ | 118 |  |  | $ | (1,881) |  |  | $ | 23,135 |
The following unrealized and realized gains or losses from our investment in the Life Sciences Portfolio are recorded in the change in fair value of equity securities and gain or loss on sale of equity securities, respectively, in the condensed consolidated statements of operations and comprehensive income (loss):
|  |  | Three Months Ended March 31,
|  |  |  |  | 2025 |  | 2024
|  |  |  |  | (In thousands)
Change in fair value of equity securities of public companies |  |  |  |  | $ | — |  |  | $ | (28,581) |
Gain on sale of equity securities of public companies |  |  |  |  | — |  |  | 28,581 |
Net realized and unrealized gain |  |  |  |  | $ | — |  |  | $ | — |

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of unrealized gains and losses on investments. + References No definition available. + Details
Name: | us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration